Neuland accelerates peptide manufacturing expansion to meet rising customer demand

Big Picture Bio founded to identify, design and optimise promising cancer combination therapies

- New company founded by Deep Science Ventures veterans closes £1.5M (~$2M USD) pre-seed round and secures £700K (~$950K USD) Innovate UK funding - Founding team and advisors bring expertise from Deep Science Ventures, AstraZeneca, Exscientia and PhoreMost - Initially focused on cancer and immune-mediated diseases, Big Picture Bio’s platform identifies optimal combinations of drugs and sequencing to minimise residual disease

Avenda Health Expands Private Practice Network with the Deployment of Unfold AI at Arizona Urology, Bringing AI Prostate Cancer Mapping to the Southwest

Leading Phoenix urology practice adopts advanced AI cancer mapping to personalize surgical planning, enhance patient visualization, and pave the way for outpatient treatments

ZeOmega Named a Leader in IDC MarketScape: U.S. Care Coordination Application 2026 Vendor Assessment

Complex-molecule specialist Shilpa CDMO launches at CPHI Milan

Reckitt Plans $600 Million U.S. Expansion Across R&D and Manufacturing

Reckitt plans to invest up to $600 million across New Jersey and North Carolina to strengthen U.S. R&D, innovation and OTC manufacturing. The investment will create a new science and innovation center and expand its largest U.S. OTC facility to support Mucinex, Move Free and future healthcare product demand.

Magnitude Biosciences secures £1.3m investment to scale pioneering in vivo drug discovery platform

Zymo Research Ranks Among Top Performers in International AI Antibody Design Challenge

Dear Bio-IT World Editorial Team, My name is Nora Flynn and I am reaching out from Zymo Research to share our latest press release announcing Zymo Research’s top-tier performance in the AIntibody Design Challenge, an international benchmark of AI-driven antibody discovery published recently in Nature Biotechnology. We believe this development will be of significant interest to your audience, particularly those working in computational biology, protein engineering, drug discovery, bioinformatics, and artificial intelligence. The press release highlights Zymo Research’s top-four ranking in the affinity maturation challenge, where generated antibody variants demonstrated up to 75-fold improved binding affinity. Additionally, the press release reaffirms the company's continued investment in AI-driven protein design. Overall, the blinded, prospective AIntibody benchmark demonstrates the capabilities of AI-guided protein engineering paired with experimental validation, which could be especially valuable for researchers and professionals developing AI-enabled biologics discovery platforms, evaluating protein design technologies, or applying machine learning to therapeutic antibody optimization. We invite you to review the attached press release as an advance preview ahead of its public release tomorrow, September 16, 2026, at 6:00 AM PT. We would be grateful if you would consider sharing this news with your readers once the announcement is made public. If you require any additional information, high-resolution images, or would like to arrange an interview with one of our experts, please do not hesitate to reach out. I look forward to the opportunity to collaborate with your team. Thank you for your time and consideration.

Malvern Panalytical launches Zetasizer Core – an industry first in biologics plate-based stability screening

Malvern, UK, 15th September 2026 / Sciad Communications / Malvern Panalytical today announces the launch of the Zetasizer Core, a next generation stability screening instrument designed to deliver greater throughput, deeper mechanistic insight and more efficient workflows for early-stage biologics discovery.

Unilabs Advances Digital Pathology Across Europe with Proscia, Shaping the Future of Precision Medicine

Unifying pathologists, workflows, and AI to amplify expertise

Psychedelic Medicines Approach a Historic FDA Approval Milestone with Safety Under Scrutiny

The FDA's historic psychedelic hearing highlighted a critical question: how can psychedelic medicines become accessible without compromising patient safety? As developers move closer to potential approvals, regulators must balance clinical evidence, professional oversight, workforce training, geographic access and long-term safety.

Monod Bio Licenses AI-designed Protein Technologies to SignalChem Biotech for Custom Discovery Assays

FibroFind appoints leading transplant physician Professor Andrew Fisher as Chief Medical Officer

Qinecsa selected as technology partner for Africa’s new continent-wide medicines safety platform

Qinecsa has been selected as technology partner for AfriVigilance, the African Medicines Agency’s new continent-wide medicines safety surveillance platform, with implementation already underway.

FDA Approves AstraZeneca’s Etcamah, Bringing ctDNA-Guided Treatment to Breast Cancer

AstraZeneca’s Etcamah has received FDA accelerated approval for ctDNA-guided treatment in HR-positive, HER2-negative breast cancer with ESR1 mutations. The decision could establish an earlier treatment-switch strategy based on molecular changes before cancer becomes visible on scans.

Peer-Reviewed Study Published in MDPI’s AI Journal Shows NetraAI Uncovers Clinical Trial Signals Missed by Conventional AI and Foundation Models

The study evaluated NetraAI technology across clinical datasets in schizophrenia, major depressive disorder and pancreatic cancer, benchmarking the technology against eight industry-standard predictive models. The findings show NetraAI's biological and clinical signatures successfully boosted the accuracy of all eight evaluated algorithms across every single dataset tested.

Research uncovers new driver of immunotherapy resistance in pancreatic cancer

Targeting a signal released by dormant cancer cells could help overcome resistance to immunotherapy and improve cellular therapies for pancreatic cancer.

UT-led study finds COVID-19 can awaken hidden viruses throughout the body

Researchers say dormant viruses many people harbor can reactivate during COVID-19 and may be linked to long COVID symptoms.

Panther Life Sciences Appoints Mounir Hanana as Chief Executive Officer

Hanana brings 25 years of experience scaling global technology, consumer, and manufacturing businesses at Amazon and Procter & Gamble. Founder Carlos Bhola continues as Executive Chairman, leading strategy, product vision and corporate development. Hanana joins as Panther begins commercializing its SmartPatch™ platform, starting with cosmetics and medical aesthetics and expanding to therapeutic applications.

Complex-molecule specialist Shilpa CDMO launches at CPHI Milan